The Novo Nordisk Foundation committed up to $850 million to scale Denmark’s BioInnovation Institute across Europe, expanding an innovation engine that has supported 131 startups to date. The move signals large philanthropic capital mobilizing to seed early‑stage life‑science companies. Separately, BioCentury reported increased cash flows into biotech during J.P. Morgan week, with new funds and venture commitments from Arkin, Lux, a16z and Servier among others. Deal value in 2025 hit record levels, and conference week saw heightened financing and partnership activity. The combination of philanthropic scaling, venture capital influx and strong dealmaking at JPM suggests expanded capital availability for startups and platform companies, with knock‑on effects for valuations, M&A and early clinical financing.